CSIMarket
 
Lipocine Inc   (LPCN)
Other Ticker:  
 
 
Price: $6.8900 $0.35 5.352%
Day's High: $6.98 Week Perf: 8.16 %
Day's Low: $ 6.41 30 Day Perf: 51.43 %
Volume (M): 19 52 Wk High: $ 7.15
Volume (M$): $ 132 52 Wk Avg: $3.96
Open: $6.58 52 Wk Low: $2.31



 Market Capitalization (Millions $) 36
 Shares Outstanding (Millions) 5
 Employees -
 Revenues (TTM) (Millions $) -3
 Net Income (TTM) (Millions $) -16
 Cash Flow (TTM) (Millions $) 2
 Capital Exp. (TTM) (Millions $) 0

Lipocine Inc
Lipocine Inc is a pharmaceutical company based in the United States that specializes in the development of oral drug delivery systems. The company focuses on creating innovative solutions to improve the absorption and bioavailability of orally administered drugs. Lipocine aims to address unmet medical needs through their proprietary technology platforms, which include methods to enhance solubility, enable controlled release, and improve overall drug performance. They primarily develop therapies in the areas of men's and women's health, with a particular focus on hormone replacement therapy and reducing the risk of cardiovascular disease.


   Company Address: 675 Arapeen Drive Salt Lake City 84108 UT
   Company Phone Number: 994-7383   Stock Exchange / Ticker: NASDAQ LPCN
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Lipocine Inc

Lipocine Inc's Revenue Soars, But Challenges Loom Ahead2.



Lipocine Inc, a pharmaceutical company, recently announced an impressive revenue rise of 164.577% in the October to December 31, 2023 period, indicating potential growth prospects. However, a deep dive into the financials reveals a concerning trend of widening deficits and an overall negative performance. This article will explore the factors pushing Lipocine Inc towards a bearish outlook and delve into the implications of its financial performance.
Revenue Growth Masks Persistent Deficits:
While Lipocine Inc celebrated a substantial revenue improvement in the last quarter, it is important to take note of the widening deficit experienced by the company. Despite the positive revenue growth, the deficit expanded to $-0.44 million, underscoring the underlying financial struggles faced by the company.

Lipocine Inc

Leading Pharmaceutical Preparations Company Exceeds Expectations in Fiscal Year Ending September 30, 2023



Lipocine Inc, a pharmaceutical company traded on the NASDAQ exchange, has experienced a significant drop in stock value over the past five trading days. However, it is important to assess the company's performance in a broader context. This article will explore Lipocine Inc's recent financial results and evaluate how they might influence the company's future prospects.
1. Stock Performance:
Over the past five trading days, Lipocine Inc's stock has declined by -9.75%. Despite this short-term setback, the company has delivered an impressive year-to-date performance of 505.33%, indicating a strong overall growth trajectory. Furthermore, its current stock value is trading 9.7% above its 52-week average, suggesting positive market sentiment towards Lipocine Inc.

Lipocine Inc

Breaking: Lipocine Inc Faces Soaring Deficit, Raising Concerns About Financial Future - Exclusive Details Inside!

Lipocine Inc, a major pharmaceutical preparations company, has reported a disastrous financial performance for the quarter ending June 30, 2023. The company witnessed a significant decline in revenue, which dropped by a staggering -97.466% to only $0.03 million. Additionally, their net loss per share has swollen to $-0.68, a substantial increase from the same reporting period last year.
This gloomy financial report stands in sharp contrast to the rest of the major pharmaceutical preparations industry, which saw a 2.14% increase in revenue from the comparable reporting period a year ago. In comparison to the previous reporting period, Lipocine Inc's revenue has tumbled by -82.07% from $0.15 million to its current level. The net deficit for the financial time-frame ending June 30, 2023, amounted to $-3.549 million, surpassing the $-2.632 million loss recorded a year ago.

Lipocine Inc

Lipocine Inc faces steep decline in revenue, but sees glimmer of hope for 2023

Lipocine Inc, a pharmaceutical company focused on developing innovative therapies for men's and women's health, has had a disappointing start to the year 2023. In their financial reporting period from January to March 31, 2023, the company saw their revenue plummet by a staggering -99.017%, falling to a mere $0.15 million. This is a massive decline from the same financial reporting period a year before. Furthermore, the net deficit per share has increased to $-0.04 from the previous year, which also saw a net deficit of $-0.04 per share.
However, despite this discouraging performance from the previous year, there is a glimmer of hope for the first quarter of 2023. Sequentially, the revenue has turned positive from a negative of $-16,140.84 million, indicating that there may be an upward momentum in the future. Despite this positive development, it is worth noting that the company's net loss for the first quarter stood at a staggering $-3.870 million instead of net earnings of $12.624 million that were seen in the same financial reporting period a year before.






 

Lipocine Inc's Segments
 
 
• View Complete Report
  Company Estimates  
  Revenue Outlook
Lipocine Inc does not provide revenue guidance.

Earnings Outlook
Lipocine Inc does not provide earnings estimates.

 
Geographic Revenue Dispersion




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com